enGene has expanded its debt facility with Hercules Capital to up to $125 million, securing additional non-dilutive financing to support the planned Biologics License Application for its lead bladder cancer gene therapy, detalimogene voraplasmid, and to prepare for potential U.S. commercialization. The amended agreement immediately advances $25 million to refinance existing debt and provides access to up to $100 million in additional term loan tranches tied to clinical, regulatory and commercial milestones, bolstering enGene’s balance sheet and giving it greater financial flexibility as it moves from late-stage development toward a possible market launch in a competitive bladder cancer treatment landscape.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.